PDCD1 and non-small cell lung carcinoma: Therefore, building upon previous research, we conducted a multicenter, head-to-head real-world retrospective study to investigate differences in efficacy among the six PD-1 inhibitors that are frequently used as first-line treatment for advanced NSCLC in clinical practice.